KR20230021009A - 항바이러스 치료로서의 아젤라스틴 - Google Patents

항바이러스 치료로서의 아젤라스틴 Download PDF

Info

Publication number
KR20230021009A
KR20230021009A KR1020227045014A KR20227045014A KR20230021009A KR 20230021009 A KR20230021009 A KR 20230021009A KR 1020227045014 A KR1020227045014 A KR 1020227045014A KR 20227045014 A KR20227045014 A KR 20227045014A KR 20230021009 A KR20230021009 A KR 20230021009A
Authority
KR
South Korea
Prior art keywords
azelastine
virus
cov
sars
antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045014A
Other languages
English (en)
Korean (ko)
Inventor
에스테르 나지
가보르 나지
발레리아 스지자토
로버트 콘라트
Original Assignee
세비나 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20184767.0A external-priority patent/EP3936132A1/en
Application filed by 세비나 게엠베하 filed Critical 세비나 게엠베하
Publication of KR20230021009A publication Critical patent/KR20230021009A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227045014A 2020-05-29 2021-05-28 항바이러스 치료로서의 아젤라스틴 Pending KR20230021009A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20177451 2020-05-29
EP20177451.0 2020-05-29
EP20184767.0 2020-07-08
EP20184767.0A EP3936132A1 (en) 2020-07-08 2020-07-08 Azelastine as antiviral treatment
EP20195740 2020-09-11
EP20195740.4 2020-09-11
EP21171333 2021-04-29
EP21171333.4 2021-04-29
PCT/EP2021/064338 WO2021239943A1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment

Publications (1)

Publication Number Publication Date
KR20230021009A true KR20230021009A (ko) 2023-02-13

Family

ID=76059910

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045014A Pending KR20230021009A (ko) 2020-05-29 2021-05-28 항바이러스 치료로서의 아젤라스틴

Country Status (21)

Country Link
US (3) US20230201216A1 (https=)
EP (2) EP3934653B1 (https=)
JP (1) JP2023529025A (https=)
KR (1) KR20230021009A (https=)
CN (1) CN116406273A (https=)
AU (1) AU2021279280A1 (https=)
BR (1) BR112022023897A2 (https=)
CA (1) CA3184167A1 (https=)
DK (1) DK3934653T3 (https=)
ES (1) ES2937145T3 (https=)
FI (1) FI3934653T3 (https=)
HU (1) HUE060929T2 (https=)
IL (1) IL298543A (https=)
JO (1) JOP20220319B1 (https=)
LT (1) LT3934653T (https=)
MX (1) MX2022015074A (https=)
PL (1) PL3934653T3 (https=)
RS (1) RS63940B1 (https=)
SI (1) SI3934653T1 (https=)
SM (1) SMT202300036T1 (https=)
WO (1) WO2021239943A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) * 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE3836579A1 (de) * 1987-11-13 1989-05-24 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP2008285474A (ja) 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2021207213A2 (en) * 2020-04-07 2021-10-14 University Of Florida Research Foundation, Incorporated Methods to prevent sars-cov-2 infection and treat covid-19
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
CN113521289A (zh) * 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Also Published As

Publication number Publication date
AU2021279280A1 (en) 2023-01-05
EP3934653A1 (en) 2022-01-12
SMT202300036T1 (it) 2023-03-17
MX2022015074A (es) 2023-02-16
PL3934653T3 (pl) 2023-03-13
US11273163B2 (en) 2022-03-15
EP4190333A1 (en) 2023-06-07
RS63940B1 (sr) 2023-02-28
HUE060929T2 (hu) 2023-04-28
EP3934653B1 (en) 2022-11-09
FI3934653T3 (fi) 2023-03-01
IL298543A (en) 2023-01-01
BR112022023897A2 (pt) 2023-04-04
ES2937145T3 (es) 2023-03-24
WO2021239943A1 (en) 2021-12-02
SI3934653T1 (sl) 2023-04-28
CN116406273A (zh) 2023-07-07
CA3184167A1 (en) 2021-12-02
JOP20220319B1 (ar) 2024-12-22
JP2023529025A (ja) 2023-07-06
US11433080B2 (en) 2022-09-06
US20230201216A1 (en) 2023-06-29
US20210369730A1 (en) 2021-12-02
LT3934653T (lt) 2023-02-27
DK3934653T3 (da) 2023-02-13
US20220143040A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
RU2769317C2 (ru) Способы лечения гриппа
Leneva et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses
US10456440B2 (en) Anti-infective strategy against influenza virus and S. aureus coinfections
KR102233826B1 (ko) 바이러스 감염을 치료하기 위한 티아졸리드 화합물
JP6006292B2 (ja) インフルエンザウイルス複製を阻害するための方法および医薬組成物
CN111420024A (zh) 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
US11433080B2 (en) Antiviral treatment
CN114007598A (zh) 用于治疗病毒和细菌感染的新型mek抑制剂
US20230225988A1 (en) Antiviral use of calixarenes
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения
WO2014146218A1 (zh) 马替麦考酚酯或其盐类用于制备抗流感病毒之药物的用途
JPWO2003035052A1 (ja) ウイルス感染予防・治療剤
EP3936132A1 (en) Azelastine as antiviral treatment
HK40087524A (zh) 氮卓斯汀用作抗病毒治疗
Kandula et al. Knowledge, concept on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A review of the literature and future perspective
CN114377009A (zh) Sb216763在制备抗流感病毒药物中的应用
US20240165096A1 (en) Anti Viral Therapy
CN114377015B (zh) 萘哌地尔在制备抗流感病毒药物中的应用
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用
WO2020216349A1 (zh) 一种肠道病毒抑制剂
HK40090314A (zh) 治疗严重急性呼吸综合征的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902